|
Oncology
Cardiovascular
diseases
Immune and
inflammatory diseases
Metabolic
diseases
Central nervous
system (CNS) diseases
|
Provided strategic planning support and technology assessments for large
and small biotechnology companies, major research products companies, and
financial services companies. Technology and therapeutic areas included
genomics, proteomics, other drug discovery technologies and applications,
cancer, metabolic diseases, and infectious diseases.
Provided technology, scientific, and medical inputs as a key member of
a team developing a technology and market-modeling database for a major
pharmaceutical company, to guide resource allocation and new product strategy
decisions in the area of diabetes and obesity drugs.
Assessed early-stage pipeline drug candidates in diabetes, obesity, and
immune and inflammatory diseases for major pharmaceutical companies, in
order to assist the companies in project selection and resource allocation
decisions.
Assisted with initial planning for a major project to find novel approaches
to drug discovery for a neurodegenerative disease.
Identified and assessed opportunities in the life sciences for a major
Japanese producer of plastics products, including microfluidics and protein
arrays. Further assessed opportunities for the application of protein arrays
to drug discovery and diagnostics, devised market-entry and partnering
strategies, and identified potential North American and European partners.
As a result of our efforts, the client entered into an R&D collaboration
with a leading U.S. developer of protein arrays.
Produced a proprietary report on recent advances in the area of human adult
and embryonic stem cells for the research products division of a major
corporation, and made recommendations on developing potential commercial
opportunities in the stem cell area. Further assessed opportunities for
the same client in leading edge cell culture technologies that are applicable
to stem cell and developmental biology R&D, drug discovery, in vitro
ADME-Tox, and tissue engineering.
Assessed opportunities in clinical genotyping applications of DNA microarrays
for a leading U.S. corporate R&D laboratory contemplating a spin-off
venture.
Produced a proprietary report on recent developments in glycobiology, in
order to assist a client to identify and assess potential business opportunities
in that area.
Analyzed the market potential of a sample of likely early-stage products
and services of a drug delivery start-up firm, in order to assist a technology
incubator to determine the valuation of the company.
Performed due diligence on emerging and established biotechnology companies
and their technologies and businesses for potential partner companies,
as well as corporate funding and venture capital firms, in order to enable
them to make informed partnering and investment decisions.
About Haberman Associates |
Home pageCopyright © 1999-2008 Haberman Associates